Zacks Research Analysts Increase Earnings Estimates for ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research raised their Q1 2026 earnings per share estimates for Esperion Therapeutics in a note issued to investors on Monday, April 28th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn ($0.19) per share for the quarter, up from their previous estimate of ($0.20). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' FY2026 earnings at ($0.40) EPS and Q1 2027 earnings at $0.03 EPS.

Several other research analysts have also weighed in on the stock. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Friday, April 25th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Esperion Therapeutics in a research note on Friday, April 25th. JMP Securities reiterated a "market outperform" rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Finally, The Goldman Sachs Group lowered their target price on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $6.42.

Esperion Therapeutics Trading Down 1.4 %

Shares of ESPR traded down $0.02 during trading hours on Wednesday, reaching $1.08. The company had a trading volume of 1,504,457 shares, compared to its average volume of 5,659,797. Esperion Therapeutics has a 12-month low of $0.82 and a 12-month high of $3.94. The firm has a 50 day simple moving average of $1.31 and a 200-day simple moving average of $1.92. The company has a market capitalization of $213.01 million, a price-to-earnings ratio of -1.68 and a beta of 0.75.

Institutional Trading of Esperion Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wasatch Advisors LP boosted its holdings in shares of Esperion Therapeutics by 4.9% during the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock worth $53,861,000 after purchasing an additional 1,136,245 shares during the last quarter. Geode Capital Management LLC grew its holdings in Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company's stock valued at $7,148,000 after buying an additional 171,609 shares during the period. Two Sigma Advisers LP increased its stake in shares of Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock valued at $7,956,000 after acquiring an additional 16,100 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Esperion Therapeutics by 48.6% during the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock worth $6,862,000 after acquiring an additional 1,020,243 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Esperion Therapeutics by 18.6% in the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock worth $5,399,000 after acquiring an additional 385,099 shares during the last quarter. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.